These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 31062483)

  • 1. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.
    Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM
    J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.
    Briani C; Di Pietropaolo M; Marignani M; Carbonetti F; Begini P; David V; Iannicelli E
    J Gastrointest Cancer; 2018 Sep; 49(3):302-310. PubMed ID: 28547117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining the Arterial Phase of Contrast-Enhanced Ultrasonography, Gadoxetic Acid-Enhanced Magnetic Resonance Imaging and Diffusion-Weighted Imaging in the Diagnosis of Hepatic Nodules ≤20 mm in Patients with Cirrhosis.
    Zhou Y; Jing X; Zhang X; Ding J; Wang Y; Zhou H; Zhang Q; Chen Y; Yue W
    Ultrasound Med Biol; 2019 Mar; 45(3):693-701. PubMed ID: 30606633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
    Kim JE; Kim SH; Lee SJ; Rhim H
    AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of benign hypervascular hepatocellular nodules in alcoholic liver cirrhosis: differentiation from hypervascular hepatocellular carcinoma.
    Kobayashi S; Matsui O; Kamura T; Yamamoto S; Yoneda N; Gabata T; Terayama N; Sanada J
    J Comput Assist Tomogr; 2007; 31(4):557-63. PubMed ID: 17882031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing "pseudo-washout" on gadoxetic acid-enhanced hepatic MRI: value of diffusion-weighted imaging in the differential diagnosis of small lesions.
    Nam SJ; Yu JS; Cho ES; Kim JH; Chung JJ
    Clin Radiol; 2017 Mar; 72(3):247-254. PubMed ID: 27789027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
    Han SB; Kim YK; Min JH; Ha SY; Jeong WK; Lee WJ
    Acta Radiol; 2018 Apr; 59(4):393-401. PubMed ID: 28760004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.
    Moon JY; Kim SH; Choi SY; Hwang JA; Lee JE; Lee J
    Jpn J Radiol; 2018 Aug; 36(8):489-499. PubMed ID: 29876721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
    Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
    J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
    Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
    World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
    Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
    AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T.
    Lim S; Kim YK; Park HJ; Lee WJ; Choi D; Park MJ
    J Magn Reson Imaging; 2014 May; 39(5):1238-45. PubMed ID: 24136725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
    Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
    Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.